With an annual incidence between 8 and 15 per 100,000 population in the period from 2009 to 2013, Slovenia has one of the highest notified incidences of tick-borne encephalitis (TBE) in Europe. TBE vaccination coverage remains at about 7.3%. To inform vaccination policy, we used surveillance data from 2009 to 2013 to calculate the overall and age- and sex-specific mean annual TBE incidence. We estimated disability-adjusted life years (DALYs) with 95% uncertainty intervals (UI), using the Burden of Communicable Diseases in Europe approach from the European Centre for Disease Prevention and Control. The mean annual incidence was 11.6 per 100,000 population, peaking in older age groups (50–74 years: 18.5/100,000) while relatively lower among children (5–14 years: 10.2/100,000). We estimated an overall 10.95 DALYs per 100,000 population per year (95% UI: 10.25–11.65). In contrast to the TBE incidence, the disease burden in children aged 5–14 years was higher than in adults aged 50–74 years: 17.31 (95% UI: 14.58–20.08) and 11.58 (95% UI: 10.25–12.91) DALYs per 100,000 stratum-specific population, respectively. In a limited resource setting where prioritisation of TBE vaccination strategies is required, vaccination programmes targeting children may have a higher impact on disease burden.

Introduction

Tick-borne encephalitis (TBE) is a vector-borne disease caused by the TBE virus [1]. It typically presents as a two-phased illness [2–4]. The first phase is associated with symptoms such as fever, fatigue, headache, myalgia and nausea. The second phase involves the nervous system with symptoms related to meningitis and/or encephalitis. Life-long sequelae can have an important impact on the quality of life of those affected [5]. TBE cases notified in Europe have surged in the last three decades with an estimated increase of 193% [6–8].
Overall and age- and sex-specific annual burden of TBE in Slovenia in order to inform vaccination policy in a setting with limited resources.

Methods

Model
To estimate the burden of TBE we used the pathogen-based incidence approach developed by the European Centre for Disease Prevention and Control (ECDC) Burden of communicable diseases in Europe project (BCoDE) [18-20]. The burden was expressed in DALYs. DALYs have two components: years of life lost due to premature death (YLL) and healthy years of life lost due to disability (YLD) [21].

We used a disease model (outcome tree) based on the current knowledge of the disease progression pathway, linking all health outcomes related to TBE with the initial infection. Starting with the infection a case moved through the outcome tree transitioning into different health outcomes according to different conditional transition probabilities (i.e. probability of occurrence of each health outcome), exiting the tree with a resolved infection, with a life-long disability or with a fatal outcome. In order to measure YLL, life expectancy was based on the standard reference life table developed within the Global Burden of Disease 2010 project [22]. To measure YLD, each health outcome was characterised by a disease duration and a disability weight. Disability weights quantify health losses to reflect the disability experienced by someone living with a health issue. Based on the severity of the disease, they range from 0 (full health) to 1 (death). The disability weights were generated for BCoDE and the Global Burden of Disease study (GBD) 2013 through elicitation methods [23,24]. The outcome tree for TBE used in our model (Figure 1) was based on a thorough review of published studies and on the opinion of ECDC experts [25]. All parameters included in the outcome tree, conditional transition probabilities, durations and disability weights were based on published studies and entailed a certain level of uncertainty. The uncertainty was modelled by incorporating ranges using either uniform or Pert distributions [26] and quantified by performing Monte Carlo simulations with 10,000 iterations to obtain 95% uncertainty intervals (UI). In order to assess age groups of interest for vaccination strategies, we compared the median DALYs and their 95% UIs.

Input data
The ECDC BCoDE toolkit was used for DALY estimation [25]. Input data for the model were the mean annual numbers of meningoencephalitic TBE cases notified to the Slovenian national surveillance system for communicable diseases from 2009 to 2013. They were stratified by 5-year age groups and by sex. For those calculations where a population estimate was required, we used the 2011 population data for Slovenia obtained from Eurostat [27]. The main type of input data for TBE in the BCoDE toolkit was the number of symptomatic infections (first phase of the disease); to obtain this, surveillance data were multiplied by the appropriate transitional probabilities as specified by the TBE outcome tree. No time discounting was applied, thus future and present disabilities were weighted equally.

Results
From 2009 to 2013, a total of 1,190 cases (58% males) of TBE in their meningoencephalitic phase were notified in Slovenia, with a mean of 238 cases/year. The median age at diagnosis was 51 years (range: 1–86 years). The mean annual incidence of meningoencephalitic TBE was 11.6 per 100,000 population (9.6/100,000 for females and 13.6/100,000 for males). Incidence was higher in older individuals (50–74 years: 18.5/100,000) than in children (5–14 years: 10.2/100,000). Data by 5-year age groups and by sex are presented in Figure 2.

The estimated DALYs per year were 224.52 (95% UI: 210.14-238.84), corresponding to 10.95 DALYs per 100,000 per year (95% UI: 10.25-11.65). Each case of TBE accounted for an average of 0.23 DALYs (95% UI: 0.22–0.24) In the Table, DALYs and their components (YLL and YLD) are presented for all health outcomes related to TBE. YLDs per year accounted for 67% of the total disease burden. Late sequelae, following the meningoencephalitic phase of the disease, contributed to 63% of the DALYs per year.

FIGURE 1
Outcome tree for tick-borne encephalitis virus infection

<table>
<thead>
<tr>
<th>Health Outcome</th>
<th>Disability Weight</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic infection</td>
<td>0.051 (0.039-0.06)</td>
<td>0.014 years (0.005-0.019)</td>
</tr>
<tr>
<td>Symptomatic infection</td>
<td>0.447 (0.391-0.501)</td>
<td>0.041 years (0.027-0.192)</td>
</tr>
<tr>
<td>Meningoencephalitic phase</td>
<td>0.202 (0.167-0.242)</td>
<td>1 year</td>
</tr>
<tr>
<td>Post-encephalitic TBE syndrome</td>
<td>0.056 (0.044-0.067)</td>
<td>Remaining life expectancy</td>
</tr>
<tr>
<td>Chronic post-encephalitic TBE syndrome</td>
<td>0.056 (0.044-0.067)</td>
<td>Remaining life expectancy</td>
</tr>
<tr>
<td>Chronic post-encephalitic TBE syndrome</td>
<td>0.056 (0.044-0.067)</td>
<td>Remaining life expectancy</td>
</tr>
<tr>
<td>Fatal outcome</td>
<td>0.526 (0.469-0.586)</td>
<td>0.0137 years</td>
</tr>
</tbody>
</table>

DW: disability weight; R: resolution of infection; TBE: tick-borne encephalitis.
The group of 50–54-year-old women and the group of 25–29-year-old men had the highest point estimates of DALYs per year with 10.56 (95% UI: 7.34–14.03) and 13.02 (95% UI: 9.25–17.49) DALYs per year respectively. When looking at both sexes together, the 50–54 and 55–59-year-olds accounted for the highest number of DALYs, 21.08 (95% UI: 14.91–28.40) and 20.48 (95% UI: 14.48–27.70), respectively.

In terms of DALYs per 100,000 stratum-specific population, the highest burden point estimate was among the 5–9-year-olds: 19.29 DALYs per 100,000 stratum-specific population per year (95% UI: 15.41–23.90) with 16.62 DALYs (95% UI: 11.48–22.51) and 21.69 DALYs per 100,000 per year (95% UI: 15.12–29.28) for girls and boys, respectively. Data by 5-year age groups and by sex are presented in Figure 3.

The group of 50–74-year-olds had a lower TBE burden estimate of 11.58 (95% UI: 10.25–12.91) DALYs per 100,000 stratum-specific population per year in comparison to the 5–14-year-olds with a burden of 17.31 (95% UI: 14.58–20.08) DALYs per 100,000 stratum-specific population per year (Figure 4).

Discussion
In this paper we present the overall and the age- and sex-specific annual burden of TBE in Slovenia expressed in DALYs. The use of DALYs integrates mortality and morbidity from TBE in a single composite health metric, giving a comprehensive estimate of the impact of this disease on population health.

An analysis of notified TBE cases in the 5-year period from 2009 to 2013 confirms Slovenia as one of the countries, together with the Baltic states and the Russian Federation, where reported incidence per 100,000 is the highest in Europe [11,28]. With an estimate of 10.95 DALYs per 100,000 per year (95% UI: 10.25–11.65), TBE has an important impact on the health of the Slovenian population. In accordance with input incidence data, we found consistently higher burden point estimates in male persons across all ages. According to the BCoDE 2009–13 study, the estimated burden of TBE in Slovenia was nine times higher than the corresponding estimated burden of TBE measured in DALYs per 100,000 population per year for the EU and European Economic Area (EEA) for the same time period [29]. Moreover, the impact of TBE on the Slovenian population is comparable to that of healthcare-associated neonatal sepsis (16.8 DALYS/100,000) according to a recent study on healthcare-associated infection in the EU/EEA [30].
Looking at incidence data alone, older age groups (50–74-year-olds) appeared most affected by TBE in Slovenia. However, the use of DALYs identified children (5–14-year-olds) as the group with a higher burden. This difference in impact of TBE would not have been detected, if we had limited our assessment to incidence data, ignoring the combined effects of morbidity, short- and long-term sequelae and mortality. Other countries with a similar TBE incidence profile as Slovenia could profit from this approach to identify groups with important burden, particularly when informing decision makers about the allocation of limited resources for targeted public health interventions (i.e. vaccination).

Vaccination is regarded as the most effective preventive measure for TBE [11]. Studies have shown a 96–99% field effectiveness in persons receiving three doses following the recommended schedule [12,13]. In neighbouring Austria, an estimated 88% of the general population are vaccinated with at least one dose, while 58% are vaccinated regularly following the advised schedule [13]. Austria has managed to reduce the number of TBE cases by 90% by increasing its vaccination rate from 6% in 1980 to its current level [13]. Despite the fact that vaccination has been recommended in Slovenia for decades, only 12% of the population was vaccinated with at least one dose by 2007 and only 7.3% get vaccinated regularly following the advised schedule [31].

TBE vaccination remains a self-paid expense for the majority of the population. The costs are covered by the mandatory insurance system or by the employer only in case of occupational exposure or exposure during education or training. Data from 2007 show that only 4.6% of the population paid themselves for TBE vaccination [32]. A recent study from Šmit et al., estimating DALYs of TBE in Slovenia using the GBD project methodological approach, supports the need for a public health strategy aimed at increasing the national vaccination coverage [32]. Multiple factors influencing the decision to get vaccinated against TBE (knowledge, trust, accessibility, cost) should be considered when planning strategies aimed at increasing vaccination coverage [33]. Projections, however, show that the impact of a vaccine subsidy, making the vaccine free of charge, could alone increase coverage by 45%, and even more in low-income households [34].

Increasing TBE vaccination coverage should be considered as an option for intervention to reduce the impact of TBE [10,32]. In the presence of limited resources, the implementation of such a measure could be difficult in the short term. Our results suggest that effective prevention of TBE in children would have the highest impact in terms of DALYs of TBE averted. This novel insight in the distribution of TBE burden should be considered when prioritising access to TBE vaccination and could improve previous recommendations originating from incidence data alone, where the focus was mainly on older age groups [10].

Prioritising vaccination in children could be easier thanks to the well-functioning Slovenian national childhood immunisation programme. It is also important to take into account the need for booster doses of the TBE vaccine. In the age groups of interest, a three-dose primary vaccination schedule with a first booster dose after 3 years and further boosters every 5 years is recommended to maintain seropositivity [35]. A recent study showed that a schedule that includes the first booster dose yields a high and long-lasting (> 5 years) immune response, thus suggesting that subsequent TBE booster intervals could be extended beyond the current recommendation [36]. Considering the financial implications of lifelong booster doses (and the different schedules that apply at different ages), age-specific cost-effectiveness studies are needed to inform decisions on the extent to which TBE vaccine can be subsidised in order to achieve the highest level of immunopersistence and impact on TBE burden in a cost-effective manner.

We considered prioritising the most affected areas or regions as an alternative approach. Although some regions in Slovenia are more affected than others, TBE occurs throughout the country. Considering the epidemiological situation of TBE in Slovenia, the country’s relatively small area and population size, as well as the mobility of the population between regions, we consider this approach could be potentially misleading and lead to health inequalities. Other countries where restricted areas or regions are affected could consider a modelling approach stratified by region.

This study has certain limitations. The outcome tree describing the progression pathway of the
disease assumes no differences in disease progression between different age groups. Lifelong sequelae make an important contribution to the overall burden, especially in the younger age groups. The disease in children is commonly regarded as mild, but evidence is increasing for the relevance of severe acute disease and long-term sequelae of TBE in children, as well as for the lack of knowledge around the matter [5,37-46]. The uncertainty around the disease progression, overall and for different age groups, can lead to an over- or underestimation of the burden overall and in different age groups. Future study of the disease progression of TBE in different age groups is needed and could improve the accuracy of the model. Another limitation of our study is that the data set used for input in the model was not corrected for underestimation (due to under-reporting and under-ascertainment) of the surveillance system [47]. At the moment of writing, data on underestimation of TBE notification were not available. However, taking into consideration the structure of the morbidity surveillance pyramid [47], we can assume that the notified data were still underestimating the true incidence of disease, thus leading to an underestimation of our burden estimates.

DALYs are a composite health metric highly dependent on the assumptions made; it is commonly used for ranking the relative burden of diseases within the same study, in cost-effectiveness analyses or evaluations of interventions (e.g. DALYs averted). The differences in absolute values between our results and the recent study from Šmit et al. [32] are probably due to differences in underlying assumptions and disease modeling approaches. Šmit et al. used data from a single year that had more cases than the 5-year annual average we used; they used an underestimation coefficient (4.5) for the number of cases of meningoencephalitic TBE, but we did not find enough evidence to make such assumptions; they modelled all neurological sequelae as lifelong. Moreover, Šmit et al. used higher transitional probabilities (in the age groups older than 15 years) and higher disability weights when modelling mild sequelae. Taking this into consideration, a direct comparison is not valid. Our focus on the distribution of the TBE burden across different age groups enabled us to suggest efficient options for vaccination.

Conclusion
We identified a higher burden of TBE among children aged 5–14 years than among adults aged 50–74 years despite a lower TBE incidence. Incidence data alone do not fully reflect the disease impact and should not be the only indicator to inform vaccination policy. In a limited resource setting where prioritisation of TBE vaccination strategies is required, vaccination programmes targeting children should be considered as possibly having a higher impact on disease burden. Our data could be used for future cost-effectiveness studies.

Conflict of interest
None declared.

Authors’ contributions
MF and AC were responsible for the conception and design of this study. MF drafted the first study protocol, and AC, EC, IK, MM contributed to further drafts. MF and MG collected and assembled the data. MF undertook the primary data analysis in collaboration with AC. All authors had an opportunity to contribute to the interpretation of the results. MF wrote the first draft of the manuscript, and all other authors contributed to further drafts.

<table>
<thead>
<tr>
<th>Disease / Syndrome</th>
<th>DALYs/year (95% UI)</th>
<th>DALYs/100,000 (95% UI)</th>
<th>YLL/year (95% UI)</th>
<th>YLD/year (95% UI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic infection</td>
<td>0.67 (0.61–0.73)</td>
<td>0.03 (0.03–0.04)</td>
<td>0</td>
<td>0.67 (0.61–0.73)</td>
</tr>
<tr>
<td>Meningoencephalitic phase</td>
<td>81.94 (76.77–87.15)</td>
<td>4.00 (3.74–4.25)</td>
<td>74.88 (70.14–79.56)</td>
<td>7.06 (5.92–8.36)</td>
</tr>
<tr>
<td>Post-encephalitic TBE syndrome</td>
<td>21.36 (19.87–22.91)</td>
<td>1.04 (0.97–1.12)</td>
<td>0</td>
<td>21.36 (19.87–22.91)</td>
</tr>
<tr>
<td>Paralysis</td>
<td>0.001 (0.000–0.002)</td>
<td>0</td>
<td>0.20 (0.18–0.21)</td>
<td></td>
</tr>
<tr>
<td>Residual paresis</td>
<td>34.32 (31.98–36.73)</td>
<td>1.67 (1.56–1.79)</td>
<td>0</td>
<td>34.32 (31.98–36.73)</td>
</tr>
<tr>
<td>Chronic post-encephalitic TBE syndrome</td>
<td>86.04 (79.87–92.31)</td>
<td>6.20 (5.90–6.50)</td>
<td>0</td>
<td>86.04 (79.87–92.31)</td>
</tr>
<tr>
<td>Total</td>
<td>224.52 (210.14–238.84)</td>
<td>10.95 (10.25–11.65)</td>
<td>74.88 (70.14–79.56)</td>
<td>149.64 (135.67–159.75)</td>
</tr>
</tbody>
</table>

DALYs: disability-adjusted life years; TBE: tick-borne encephalitis; UI: uncertainty interval; YLD: healthy years of life lost due to disability; YLL: years of life lost.


License and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors, 2017.